RT Journal Article SR Electronic T1 Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: case report JF European Journal of Hospital Pharmacy JO Eur J Hosp Pharm FD British Medical Journal Publishing Group SP 235 OP 236 DO 10.1136/ejhpharm-2020-002660 VO 29 IS 4 A1 Kroes, Johannes Anthon A1 Zielhuis, Sander Wilhelm A1 Bethlehem, Carina A1 Ten Brinke, Anneke A1 Van Roon, Eric Nico YR 2022 UL http://ejhp.bmj.com/content/29/4/235.abstract AB A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making.All data relevant to the study are included in the article